Semin Thromb Hemost 2020; 46(01): 038-049
DOI: 10.1055/s-0039-1696946
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Fibrinogen Supplementation and Its Indications

Oliver Grottke
1   Department of Anesthesiology, RWTH Aachen University Hospital, Aachen, Germany
,
Shuba Mallaiah
2   Liverpool Women's NHS Foundation Trust, Liverpool, United Kingdom
,
Keyvan Karkouti
3   Department of Anesthesia and Pain Management, Sinai Health System, University Health Network and Women's College Hospital, Toronto, Ontario, Canada
,
Fuat Saner
4   Department of General, Visceral and Transplant Surgery, University Hospital, University Duisburg-Essen, Essen, Germany
,
Thorsten Haas
5   Department of Anesthesia, Zurich University Children's Hospital, Zurich, Switzerland
› Institutsangaben
Funding Final stage editing was provided by Portland, supported by an unrestricted grant by Octapharma. The sponsor had no influence on the content of this article.
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
01. Oktober 2019 (online)

Abstract

Adequate plasma levels of fibrinogen are essential for clot formation, and in severe bleeding, fibrinogen reaches a critically low plasma concentration earlier than other coagulation factors. Although the critical minimum concentration of fibrinogen to maintain hemostasis is a matter of debate, many patients with coagulopathic bleeding require fibrinogen supplementation. Among the treatment options for fibrinogen supplementation, fibrinogen concentrate may be viewed by some as preferable to fresh frozen plasma or cryoprecipitate. The authors review major studies that have assessed fibrinogen treatment in trauma, cardiac surgery, end-stage liver disease, postpartum hemorrhage, and pediatric patients. Some but not all randomized controlled trials have shown that fibrinogen concentrate can be beneficial in these settings. The use of fibrinogen as part of coagulation factor concentrate based therapy guided by point-of-care viscoelastic coagulation monitoring (ROTEM [rotational thromboelastometry] or TEG [thromboelastography]) appears promising. In addition to reducing patients' exposure to allogeneic blood products, this strategy may reduce the risk of complications such as transfusion-associated circulatory overload, transfusion-related acute lung injury, and thromboembolic adverse events. Randomized controlled trials are challenging to perform in patients with critical bleeding, and more evidence is needed in this setting. However, current scientific rationale and clinical data support fibrinogen repletion in patients with ongoing bleeding and confirmed fibrinogen deficiency.

Authors' Contributions

O. G. contributed to preparing the outline. All authors contributed to the writing of the article, critically reviewing the manuscript, and approving the final version for publication.


 
  • References

  • 1 Chaiwat O, Lang JD, Vavilala MS. , et al. Early packed red blood cell transfusion and acute respiratory distress syndrome after trauma. Anesthesiology 2009; 110 (02) 351-360
  • 2 Sarani B, Dunkman WJ, Dean L, Sonnad S, Rohrbach JI, Gracias VH. Transfusion of fresh frozen plasma in critically ill surgical patients is associated with an increased risk of infection. Crit Care Med 2008; 36 (04) 1114-1118
  • 3 Vamvakas EC, Blajchman MA. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010; 24 (02) 77-124
  • 4 Grottke O. Coagulation management. Curr Opin Crit Care 2012; 18 (06) 641-646
  • 5 Weisel JW, Litvinov RI. Fibrin formation, structure and properties. Subcell Biochem 2017; 82: 405-456
  • 6 Hiippala ST, Myllylä GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81 (02) 360-365
  • 7 American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management. Anesthesiology 2015; 122 (02) 241-275
  • 8 Kozek-Langenecker SA, Ahmed AB, Afshari A. , et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: first update 2016. Eur J Anaesthesiol 2017; 34 (06) 332-395
  • 9 Rossaint R, Bouillon B, Cerny V. , et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care 2016; 20: 100
  • 10 Görlinger K, Dirkmann D, Hanke AA. , et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. Anesthesiology 2011; 115 (06) 1179-1191
  • 11 Lang T, Johanning K, Metzler H. , et al. The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia. Anesth Analg 2009; 108 (03) 751-758
  • 12 Collins PW, Solomon C, Sutor K. , et al. Theoretical modelling of fibrinogen supplementation with therapeutic plasma, cryoprecipitate, or fibrinogen concentrate. Br J Anaesth 2014; 113 (04) 585-595
  • 13 Callum JL, Karkouti K, Lin Y. Cryoprecipitate: the current state of knowledge. Transfus Med Rev 2009; 23 (03) 177-188
  • 14 Solomon C, Gröner A, Ye J, Pendrak I. Safety of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance data. Thromb Haemost 2015; 113 (04) 759-771
  • 15 Costa-Filho R, Hochleitner G, Wendt M, Teruya A, Spahn DR. Over 50 years of fibrinogen concentrate. Clin Appl Thromb Hemost 2016; 22 (02) 109-114
  • 16 Schlimp CJ, Voelckel W, Inaba K, Maegele M, Ponschab M, Schöchl H. Estimation of plasma fibrinogen levels based on hemoglobin, base excess and Injury Severity Score upon emergency room admission. Crit Care 2013; 17 (04) R137
  • 17 Meyer AS, Meyer MA, Sørensen AM. , et al. Thrombelastography and rotational thromboelastometry early amplitudes in 182 trauma patients with clinical suspicion of severe injury. J Trauma Acute Care Surg 2014; 76 (03) 682-690
  • 18 Rourke C, Curry N, Khan S. , et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost 2012; 10 (07) 1342-1351
  • 19 Schöchl H, Nienaber U, Maegele M. , et al. Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care 2011; 15 (02) R83
  • 20 Stinger HK, Spinella PC, Perkins JG. , et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma 2008; 64 (2, Suppl): S79-S85 , discussion S85
  • 21 Levy JH, Grottke O, Fries D, Kozek-Langenecker S. Therapeutic plasma transfusion in bleeding patients: a systematic review. Anesth Analg 2017; 124 (04) 1268-1276
  • 22 Pandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion 2012; 52 (Suppl. 01) 65S-79S
  • 23 Watson GA, Sperry JL, Rosengart MR. , et al; Inflammation and Host Response to Injury Investigators. Fresh frozen plasma is independently associated with a higher risk of multiple organ failure and acute respiratory distress syndrome. J Trauma 2009; 67 (02) 221-227 , discussion 228–230
  • 24 Schöchl H, Nienaber U, Hofer G. , et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010; 14 (02) R55
  • 25 Wafaisade A, Lefering R, Maegele M. , et al; Trauma Registry of DGU. Administration of fibrinogen concentrate in exsanguinating trauma patients is associated with improved survival at 6 hours but not at discharge. J Trauma Acute Care Surg 2013; 74 (02) 387-3 , discussion 393–395
  • 26 Weiss G, Lison S, Glaser M. , et al. Observational study of fibrinogen concentrate in massive hemorrhage: evaluation of a multicenter register. Blood Coagul Fibrinolysis 2011; 22 (08) 727-734
  • 27 Innerhofer P, Fries D, Mittermayr M. , et al. Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial. Lancet Haematol 2017; 4 (06) e258-e271
  • 28 Besser MW, Klein AA. The coagulopathy of cardiopulmonary bypass. Crit Rev Clin Lab Sci 2010; 47 (5-6): 197-212
  • 29 Aronson S, Nisbet P, Bunke M. Fluid resuscitation practices in cardiac surgery patients in the USA: a survey of health care providers. Perioper Med (Lond) 2017; 6: 15
  • 30 Protsyk V, Rasmussen BS, Guarracino F, Erb J, Turton E, Ender J. Fluid management in cardiac surgery: results of a survey in European cardiac anesthesia departments. J Cardiothorac Vasc Anesth 2017; 31 (05) 1624-1629
  • 31 Blome M, Isgro F, Kiessling AH. , et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005; 93 (06) 1101-1107
  • 32 Solomon C, Rahe-Meyer N, Sørensen B. Fibrin formation is more impaired than thrombin generation and platelets immediately following cardiac surgery. Thromb Res 2011; 128 (03) 277-282
  • 33 Karkouti K, Callum J, Crowther MA. , et al. The relationship between fibrinogen levels after cardiopulmonary bypass and large volume red cell transfusion in cardiac surgery: an observational study. Anesth Analg 2013; 117 (01) 14-22
  • 34 Ranucci M, Baryshnikova E, Crapelli GB, Rahe-Meyer N, Menicanti L, Frigiola A. ; Surgical Clinical Outcome REsearch (SCORE) Group. Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. J Am Heart Assoc 2015; 4 (06) e002066
  • 35 Rahe-Meyer N, Levy JH, Mazer CD. , et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy. Br J Anaesth 2016; 117 (01) 41-51
  • 36 Rahe-Meyer N, Solomon C, Hanke A. , et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology 2013; 118 (01) 40-50
  • 37 Rahe-Meyer N, Pichlmaier M, Haverich A. , et al. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study. Br J Anaesth 2009; 102 (06) 785-792
  • 38 Rahe-Meyer N, Solomon C, Winterhalter M. , et al. Thromboelastometry-guided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurysm surgery. J Thorac Cardiovasc Surg 2009; 138 (03) 694-702
  • 39 Solomon C, Schöchl H, Hanke A. , et al. Haemostatic therapy in coronary artery bypass graft patients with decreased platelet function: comparison of fibrinogen concentrate with allogeneic blood products. Scand J Clin Lab Invest 2012; 72 (02) 121-128
  • 40 Weber CF, Görlinger K, Meininger D. , et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 2012; 117 (03) 531-547
  • 41 Karkouti K, Callum J, Rao V. , et al. Protocol for a phase III, non-inferiority, randomised comparison of a new fibrinogen concentrate versus cryoprecipitate for treating acquired hypofibrinogenaemia in bleeding cardiac surgical patients: the FIBRES trial. BMJ Open 2018; 8 (04) e020741
  • 42 Saner FH, Gieseler RK, Akız H, Canbay A, Görlinger K. Delicate balance of bleeding and thrombosis in end-stage liver disease and liver transplantation. Digestion 2013; 88 (03) 135-144
  • 43 Mehta G, Gustot T, Mookerjee RP. , et al. Inflammation and portal hypertension - the undiscovered country. J Hepatol 2014; 61 (01) 155-163
  • 44 Saner FH, Abeysundara L, Hartmann M, Mallett SV. Rational approach to transfusion in liver transplantation. Minerva Anestesiol 2018; 84 (03) 378-388
  • 45 Colucci M, Binetti BM, Branca MG. , et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003; 38 (01) 230-237
  • 46 Lisman T, Leebeek FW, Mosnier LO. , et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121 (01) 131-139
  • 47 Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010; 116 (06) 878-885
  • 48 Søgaard KK, Horváth-Puhó E, Grønbaek H, Jepsen P, Vilstrup H, Sørensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009; 104 (01) 96-101
  • 49 Saner FH, Kirchner C. Monitoring and treatment of coagulation disorders in end-stage liver disease. Visc Med 2016; 32 (04) 241-248
  • 50 Blasi A, Beltran J, Pereira A. , et al. An assessment of thromboelastometry to monitor blood coagulation and guide transfusion support in liver transplantation. Transfusion 2012; 52 (09) 1989-1998
  • 51 Dötsch TM, Dirkmann D, Bezinover D. , et al. Assessment of standard laboratory tests and rotational thromboelastometry for the prediction of postoperative bleeding in liver transplantation. Br J Anaesth 2017; 119 (03) 402-410
  • 52 Hugenholtz GC, Macrae F, Adelmeijer J. , et al. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen. J Thromb Haemost 2016; 14 (05) 1054-1066
  • 53 Agarwal B, Wright G, Gatt A. , et al. Evaluation of coagulation abnormalities in acute liver failure. J Hepatol 2012; 57 (04) 780-786
  • 54 Peng HT, Nascimento B, Beckett A. Thromboelastography and thromboelastometry in assessment of fibrinogen deficiency and prediction for transfusion requirement: a descriptive review. BioMed Res Int 2018; 2018: 7020539
  • 55 Scarpelini S, Rhind SG, Nascimento B. , et al. Normal range values for thromboelastography in healthy adult volunteers. Braz J Med Biol Res 2009; 42 (12) 1210-1217
  • 56 Solomon C, Ranucci M, Hochleitner G, Schöchl H, Schlimp CJ. Assessing the methodology for calculating platelet contribution to clot strength (platelet component) in thromboelastometry and thrombelastography. Anesth Analg 2015; 121 (04) 868-878
  • 57 Nadim MK, Durand F, Kellum JA. , et al. Management of the critically ill patient with cirrhosis: a multidisciplinary perspective. J Hepatol 2016; 64 (03) 717-735
  • 58 Drolz A, Horvatits T, Roedl K. , et al. Coagulation parameters and major bleeding in critically ill patients with cirrhosis. Hepatology 2016; 64 (02) 556-568
  • 59 Kirchner C, Dirkmann D, Treckmann JW. , et al. Coagulation management with factor concentrates in liver transplantation: a single-center experience. Transfusion 2014; 54 (10 Pt 2): 2760-2768
  • 60 Sabate A, Gutierrez R, Beltran J. , et al. Impact of preemptive fibrinogen concentrate on transfusion requirements in liver transplantation: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Transplant 2016; 16 (08) 2421-2429
  • 61 World Health Organization. WHO Recommendations on Prevention and Treatment of Postpartum Haemorrhage and the WOMAN Trial. Geneva: World Health Organization; 2017
  • 62 Solomon C, Collis RE, Collins PW. Haemostatic monitoring during postpartum haemorrhage and implications for management. Br J Anaesth 2012; 109 (06) 851-863
  • 63 Charbit B, Mandelbrot L, Samain E. , et al; PPH Study Group. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007; 5 (02) 266-273
  • 64 Collins PW, Lilley G, Bruynseels D. , et al. Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study. Blood 2014; 124 (11) 1727-1736
  • 65 Cortet M, Deneux-Tharaux C, Dupont C. , et al. Association between fibrinogen level and severity of postpartum haemorrhage: secondary analysis of a prospective trial. Br J Anaesth 2012; 108 (06) 984-989
  • 66 Gayat E, Resche-Rigon M, Morel O. , et al. Predictive factors of advanced interventional procedures in a multicentre severe postpartum haemorrhage study. Intensive Care Med 2011; 37 (11) 1816-1825
  • 67 Allard S, Green L, Hunt BJ. How we manage the haematological aspects of major obstetric haemorrhage. Br J Haematol 2014; 164 (02) 177-188
  • 68 Peyvandi F, Biguzzi E, Franchi F. , et al. Elevated prepartum fibrinogen levels are not associated with a reduced risk of postpartum hemorrhage. J Thromb Haemost 2012; 10 (07) 1451-1453
  • 69 Collins PW, Cannings-John R, Bruynseels D. , et al. Viscoelastometric-guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2, a double-blind randomized controlled trial. Br J Anaesth 2017; 119 (03) 411-421
  • 70 Mallaiah S, Barclay P, Harrod I, Chevannes C, Bhalla A. Introduction of an algorithm for ROTEM-guided fibrinogen concentrate administration in major obstetric haemorrhage. Anaesthesia 2015; 70 (02) 166-175
  • 71 McNamara H, Kenyon C, Smith R, Mallaiah S, Barclay P. Four years' experience of a ROTEM®-guided algorithm for treatment of coagulopathy in obstetric haemorrhage. Anaesthesia 2019; 74 (08) 984-991
  • 72 Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990; 12 (01) 95-104
  • 73 Ignjatovic V, Ilhan A, Monagle P. Evidence for age-related differences in human fibrinogen. Blood Coagul Fibrinolysis 2011; 22 (02) 110-117
  • 74 Levy JH, Szlam F, Tanaka KA, Sniecienski RM. Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth Analg 2012; 114 (02) 261-274
  • 75 Haas T, Mauch J, Weiss M, Schmugge M. Management of dilutional coagulopathy during pediatric major surgery. Transfus Med Hemother 2012; 39 (02) 114-119
  • 76 Fries D. Dilutional coagulopathy: development, diagnostic options and management [in German]. Haemostaseologie 2006; 26 (03) (Suppl. 01) S15-S19
  • 77 Kozek-Langenecker S. Management of massive operative blood loss. Minerva Anestesiol 2007; 73 (7-8): 401-415
  • 78 Innerhofer P, Kienast J. Principles of perioperative coagulopathy. Best Pract Res Clin Anaesthesiol 2010; 24 (01) 1-14
  • 79 Faraoni D, Willems A, Savan V, Demanet H, De Ville A, Van der Linden P. Plasma fibrinogen concentration is correlated with postoperative blood loss in children undergoing cardiac surgery. A retrospective review. Eur J Anaesthesiol 2014; 31 (06) 317-326
  • 80 Haas T, Spielmann N, Restin T. , et al. Higher fibrinogen concentrations for reduction of transfusion requirements during major paediatric surgery: a prospective randomised controlled trial. Br J Anaesth 2015; 115 (02) 234-243
  • 81 National Blood Authority. Patient Blood Management Guidelines: Module 6–Neonatal and Paediatrics. Available at: https://www.blood.gov.au/pbm-module-6 . Accessed May 8, 2019
  • 82 Galas FR, de Almeida JP, Fukushima JT. , et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: a randomized pilot trial. J Thorac Cardiovasc Surg 2014; 148 (04) 1647-1655
  • 83 Guzzetta NA, Williams GD. Current use of factor concentrates in pediatric cardiac anesthesia. Paediatr Anaesth 2017; 27 (07) 678-687
  • 84 Tirotta C, Lagueruela R, Madril D. , et al. Use of human fibrinogen concentrate in pediatric cardiac surgery. Int J Anesth Anesth 2015; 2 (04) 1-6
  • 85 Haas T, Spielmann N, Restin T, Schmidt AR, Schmugge M, Cushing MM. Economic aspects of intraoperative coagulation management targeting higher fibrinogen concentrations during major craniosynostosis surgery. Paediatr Anaesth 2016; 26 (01) 77-83
  • 86 Faraoni D. Fibrinogen concentrate as first-line therapy in children undergoing cardiac surgery: promising perspectives. J Thorac Cardiovasc Surg 2015; 149 (05) 1466-1467
  • 87 Maw G, Furyk C. Pediatric massive transfusion: a systematic review. Pediatr Emerg Care 2018; 34 (08) 594-598
  • 88 Goobie SM, Haas T. Perioperative bleeding management in pediatric patients. Curr Opin Anaesthesiol 2016; 29 (03) 352-358
  • 89 Fominskiy E, Nepomniashchikh VA, Lomivorotov VV. , et al. Efficacy and safety of fibrinogen concentrate in surgical patients: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth 2016; 30 (05) 1196-1204